Ocular toxicity due to Trametinib and Dabrafenib
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To report a case of uveitis and neuroretinal detachment in a patient treated with Trametinib and Dabrafenib due to metastatic cutaneous melanoma stage IV. CASE PRESENTATION: We evaluated slit lamp examination, fundoscopy, optical coherence tomography, fluorescein and indocyanine green angiography in a 66 years old man suffering visual loss. Fundoscopy showed serous neuroretinal detachment of the fovea accompanied with white spots surrounding the fovea in both eyes. Although therapy with Trametinib and Dabrafenib was stopped uveitis anterior was seen 2 weeks later. After a year, the therapy was started again and the serous neuroretinal detachment appeared once more, however without inflammatory reaction of the anterior chamber. CONCLUSION: Patients treated with Trametinib and Dabrafenib should undergo consecutive eye examinations from the beginning of the therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Apart from p38, inhibitors of other MAPKs, when used in the context of cancer treatment, were shown to have severe uveitis as a side effect, which, although transient and manageable, must be taken into consideration when treating patients [ 192 , 193 , 194 , 195 ]”
From MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges (2023) · cites this paper as [192]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“Of the melanomas 80–90% show a mutation in BRAF V600E and 10–20% in BRAF V600 K [1].”
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810 · cited 1×
“Trametinib is applied as single agent or in combination with Dabrafenib [2].”
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21184 · Cited by 331 · cited 1×
“5% in Trametinib, chorioretinopathy with an incidence of up to 2% in both Trametinib and Dabrafenib and uveitis with unknown incidence [7].”
Transient MEK inhibitor-associated retinopathy in metastatic melanoma
Urner-Bloch, U., Urner, M., Stieger, P., Galliker, N., Winterton, N., Zubel, A., Parseval, L. M., Dummer, R., & Goldinger, S. M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu169 · Cited by 136 · cited 1×
“finding only mild and self-limiting retinopathy [10].”
Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib
Choe, C. H., McArthur, G. A., Caro, I., Kempen, J. H., & Amaravadi, R. K. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.07.003 · Cited by 113 · cited 1×
“The BRAF-inhibitor Vemurafenib, usually in combination with the MEK-inhibitor cobimetinib, was associated with both uveitis in 4% [8] and with serous retinopathy in even 26% [9].”
Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities
van der Noll, R., Leijen, S., Neuteboom, G. H. G., Beijnen, J. H., & Schellens, J. H. M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.01.003 · Cited by 108 · cited 1×
“Recently authors report of ocular complications under therapy like central serous-like chorioretinopathy, uveitis or retinal vein occlusion [4, 5].”
Rajan, A., Kim, C., Heery, C. R., Guha, U., & Gulley, J. L. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1175694 · Cited by 104 · cited 1×
“After 2 months without any therapy Nivolumab, a monoclonal antibody, was administered [6].”
McCannel, T. A., Chmielowski, B., Finn, R. S., Goldman, J., Ribas, A., Wainberg, Z. A., & McCannel, C. A. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.976 · Cited by 91 · cited 1×
“veitis [11] and multiple serous retinal detachment [12].”
Niro, A., Strippoli, S., Alessio, G., Sborgia, L., Recchimurzo, N., & Guida, M. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.07.035 · Cited by 45 · cited 1×
“Recently authors report of ocular complications under therapy like central serous-like chorioretinopathy, uveitis or retinal vein occlusion [4, 5].”
Cited by
Ocular Adverse Events Associated with Mek Inhibitors
Méndez-Martínez, S., Calvo, P., Ruiz-Moreno, O., Pardiñas Barón, N., Leciñena Bueno, J., Gil Ruiz, M. D. R., & Pablo, L. (2019) · Retina · doi:10.1097/iae.0000000000002451 · Cited by 117
Fujimura, T., Kambayashi, Y., Tanita, K., Sato, Y., Hidaka, T., Otsuka, A., Tanaka, H., Furudate, S., Hashimoto, A., & Aiba, S. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14273 · Cited by 86
Ocular Toxicity of Targeted Anticancer Agents
Fortes, B. H., Tailor, P. D., & Dalvin, L. A. (2021) · Drugs · doi:10.1007/s40265-021-01507-z · Cited by 64
“[29] MEKAR and bilateral anterior uveitis: 1 case Topical corticosteroids Y Schoenberger and Kim [318], Giuffrè et al.”
BackgroundMAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges
Moustardas, P., Aberdam, D., & Lagali, N. (2023) · Cells · doi:10.3390/cells12040617 · Cited by 63
Jeng-Miller, K. W., Miller, M. A., & Heier, J. S. (2024) · The Oncologist · doi:10.1093/oncolo/oyae014 · Cited by 41
“35 In our opinion, it is unlikely that the uveitis was associated with MEK inhibitor therapy.”
BackgroundInfluential
Metadata
- Authors
- Sarny, S., Neumayer, M., Kofler, J., & El-Shabrawi, Y.
- Affiliations
- Klinikum Klagenfurt (AT)
- Corresponding author
- Sarny, Stephanie
- Venue
- BMC Ophthalmology
- Published
- 2017-08-17
- Volume
- 17
- Issue
- 1
- Pages
- 146-146
- ISSN
- 1471-2415 (ISSN-L)
- PMC
- PMC5561643
- OpenAlex
- W2748159422
- Cited by
- 61
- References
- 12
- Citations by year
- 2025: 3 · 2024: 9 · 2023: 6 · 2022: 11 · 2021: 14 · 2020: 7 · 2019: 9 · 2018: 2
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- BMC Ophthalmology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- trametinib, dabrafenib, ocular toxicity, uveitis, metastatic cutaneous melanoma, vision loss, fundus examination
- MeSH terms
- Aged, Antineoplastic Agents, Humans, Imidazoles, Male, Oximes, Pyridones, Pyrimidinones, Retinal Detachment, Uveitis, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ocular toxicity due to Trametinib and Dabrafenib. https://app.cochat.ai/papers/10.1186/s12886-017-0541-0
- The paper
- Sarny, S., Neumayer, M., Kofler, J., & El-Shabrawi, Y. (2017). Ocular toxicity due to Trametinib and Dabrafenib. BMC Ophthalmology. https://doi.org/10.1186/s12886-017-0541-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.